The treatment with mTOR inhibitors was initiated due to SEGA in twelve patients (12/21, 57.1%), drug-resistant epilepsy in seven (7/21, 33.3%), rhabdomyomas causing arrhythmia or obstruction of blood flow in five (5/21, 28.6%), and renal angiomyolipomas and retinal hamartomas in one each (1/21, 4.8%). Here, MTOR is linked to subependymal giant cell astrocytoma.